CHPT1-LCAT rewires lipolysis towards ferroptosis

This study identifies a previously unrecognized intracellular metabolic axis involving CHPT1 and an enzymatically active pool of LCAT that selectively channels diacylglycerol into polyunsaturated cholesteryl esters to drive ferroptosis, revealing that subcellular lipid routing rather than bulk lipid abundance determines ferroptotic vulnerability and offering therapeutic potential for cancer and metabolic liver disease.

The Gist

The Big Picture: A Cellular Traffic Jam

Imagine your cells are like busy cities. Inside these cities, there are roads (metabolic pathways) where "cars" (lipids/fats) travel. Sometimes, these cars crash and cause a fiery explosion called ferroptosis. This is a specific type of cell death caused by iron and rusting fats.

Scientists have known for a while that ferroptosis is a double-edged sword:

• In Cancer: We want to cause this explosion to kill the bad cancer cells.
• In Liver Disease: We want to stop this explosion because it destroys healthy liver cells, leading to a condition called MASH (fatty liver disease).

The big mystery was: How does the cell decide which fats to send down the "explosion" road? Is it just about how many fat cars are on the road, or is it about where they are driving?

This paper says: It's all about the route, not the traffic volume.

---

The Story Unfolds

1. The "Gatekeeper" Discovery

The researchers started by looking at a specific enzyme called MAGL. Think of MAGL as a gatekeeper at a toll booth.

• Normal Job: MAGL usually breaks down a specific type of fat (Monoacylglycerol) so it can be recycled.
• The Discovery: When the scientists blocked (inhibited) this gatekeeper, the cancer cells didn't just get tired; they exploded via ferroptosis.
• The Clue: Blocking the gatekeeper caused a backup of a specific intermediate fat called DAG (Diacylglycerol). It turns out, DAG is the "licensing key" that allows the cell to be destroyed.

2. The "Detour" Sign

The researchers realized that having a lot of DAG isn't enough. The DAG has to take a specific detour.

• Normally, DAG might go one way to build cell walls (membranes).
• But in this "ferroptosis mode," DAG gets rerouted into a secret tunnel.
• Inside this tunnel, DAG is converted into Cholesteryl Esters (a type of fat that loves to rust/oxidize). These rusty fats are the actual bombs that blow up the cell.

3. The Secret Team: CHPT1 and iLCAT

How does the cell know to send DAG down this dangerous tunnel? The paper found a secret team of two enzymes working together:

1. CHPT1: The traffic cop that directs DAG into the tunnel.
2. LCAT: The mechanic that builds the rusty bombs.

Here is the twist: Everyone thought LCAT was a "secret agent" that only worked outside the cell (in the blood) to clean up cholesterol.

• The Surprise: The scientists found a hidden, intracellular pool of LCAT (let's call it iLCAT). This version stays inside the cell, specifically in the Golgi (the cell's shipping and receiving center).
• The Partnership: Inside the Golgi, CHPT1 and iLCAT hold hands. They take the DAG, turn it into a "rusty bomb" (polyunsaturated cholesteryl ester), and load it onto the cell's machinery to trigger the explosion.

4. The Two Different Outcomes

Because this mechanism is so powerful, it has opposite effects depending on the type of cell:

• Scenario A: The Cancer Cell (The Good Explosion)

  • Cancer cells are greedy and have lots of fats.
  • If we force them to take this "DAG detour" (by blocking the normal recycling path), they get flooded with rusty bombs.
  • Result: The cancer cell explodes (ferroptosis), and the tumor shrinks.
  • Analogy: It's like tricking a criminal into driving a car full of explosives into their own hideout.

• Scenario B: The Liver Cell (The Bad Explosion)

  • In liver disease (MASH), the liver is already stressed and full of fat.
  • If this "CHPT1-iLCAT" team gets too active, it turns the liver's own fat into rusty bombs.
  • Result: Healthy liver cells die, causing inflammation and scarring (fibrosis).
  • Analogy: It's like a fire department accidentally pouring gasoline on a house fire.

5. The Solution

The researchers tested their theory in mice:

• In Cancer Mice: They blocked the normal fat recycling. This forced the cancer cells to use the "DAG detour," leading to tumor death.
• In Liver Disease Mice: They used a special "silencer" (siRNA) to turn off the CHPT1 and LCAT genes only in the liver.
  • Result: The liver stopped making the rusty bombs. The inflammation went down, the liver healed, and the disease improved.

The Takeaway

This paper teaches us that location matters more than quantity. It's not just about how much fat you have; it's about where that fat is being processed inside the cell.

• The Metaphor: Imagine a factory. If you send raw materials to the "Recycling Department," everything is fine. But if you accidentally send those same raw materials to the "Bomb-Making Department," the factory blows up.
• The Lesson: By understanding the specific "address" (the Golgi) and the "workers" (CHPT1 and iLCAT) inside the Bomb-Making Department, we can either trigger the explosion to kill cancer or shut down the department to save the liver.

This discovery opens the door to new drugs that can target these specific "traffic cops" to treat cancer or liver disease without messing up the rest of the body's fat metabolism.

Technical Summary

1. Problem Statement

Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. While lipid metabolism is known to influence ferroptotic sensitivity, the specific mechanisms governing how metabolic flux is selectively routed toward pro-ferroptotic lipid species remain unclear. A critical gap exists in understanding whether ferroptotic vulnerability is determined by the bulk abundance of lipids or by the selective subcellular routing of specific lipid intermediates into distinct metabolic fates. Specifically, the role of diacylglycerol (DAG) and its downstream processing in generating lethal lipid species was not well-defined.

2. Methodology

The study employed a multi-faceted approach combining chemical genetics, lipidomics, cell biology, and in vivo disease models:

• High-Throughput Chemical-Genetic Screen: A library of 871 small molecules targeting metabolic enzymes was screened in HT-1080 fibrosarcoma cells using a ferroptosis-rescue strategy (pre-treatment with Ferrostatin-1).
• Genetic Manipulation: CRISPR-Cas9 was used to generate knockout cell lines (MAGL, ATGL, DAGLA, DAGLB, CHPT1, LCAT), and siRNA was used for knockdowns. Overexpression constructs (including signal peptide-deficient LCAT variants) were utilized to dissect protein trafficking.
• Lipidomics: Both untargeted and targeted LC-MS/MS lipidomics were performed to quantify changes in lipid species (specifically DAGs and Cholesteryl Esters) following enzyme inhibition.
• Biochemical & Cellular Assays:
  • Enzymatic Activity: In vitro acyltransferase assays using purified LCAT and dehydroergosterol (DHE) substrates.
  • Subcellular Localization: Differential permeabilization (Triton X-100 vs. Digitonin) combined with immunofluorescence to distinguish between secreted and intracellular protein pools. Co-immunoprecipitation (Co-IP) assessed protein-protein interactions.
  • Ferroptosis Markers: Measurement of lipid peroxidation (C11-BODIPY, MDA levels, 4-HNE staining) and mitochondrial morphology via Transmission Electron Microscopy (TEM).
• In Vivo Models:
  • Cancer: Xenograft models in nude mice (HT-1080 and SK-HEP-1) treated with DAGL inhibitors (DO34, KT109) and ferroptosis inducers/inhibitors.
  • Metabolic Disease: A mouse model of Metabolic Dysfunction-Associated Steatohepatitis (MASH) induced by an AMLN diet, treated with hepatocyte-targeted GalNAc-siRNAs to silence CHPT1 or LCAT.

3. Key Contributions

• Discovery of a Metabolic Axis: Identification of a previously unrecognized intracellular metabolic axis involving Choline Phosphotransferase 1 (CHPT1) and Lecithin–Cholesterol Acyltransferase (LCAT) that channels DAG into pro-ferroptotic cholesteryl esters.
• Intracellular LCAT (iLCAT): Uncovering an enzymatically active, intracellular pool of LCAT that is largely non-glycosylated and localized to the Golgi/Trans-Golgi Network (TGN), distinct from its canonical secreted role in plasma HDL metabolism.
• Subcellular Routing vs. Abundance: Establishing that ferroptotic vulnerability is dictated not by the total amount of lipolytic output, but by the selective routing of DAG into a specific lethal pathway.
• Dual Therapeutic Potential: Demonstrating that this axis can be exploited to suppress tumor growth via ferroptosis in cancer, while its inhibition ameliorates liver pathology in MASH by preventing ferroptosis.

4. Key Results

A. Lipolysis and DAG as a Central Node

• MAGL Inhibition: Inhibiting Monoacylglycerol Lipase (MAGL) sensitized cells to ferroptosis, increasing lipid peroxidation and mitochondrial shrinkage.
• ATGL vs. DAGL: Genetic ablation of Adipose Triglyceride Lipase (ATGL) conferred resistance to ferroptosis, whereas inhibition or knockout of Diacylglycerol Lipase (DAGL) potently sensitized cells. This indicated that the accumulation of DAG (caused by blocking its conversion to MAG) is the critical trigger.
• Mechanism: DAG accumulation alone was insufficient; it required specific routing. Inhibiting DAGL led to a massive accumulation of polyunsaturated cholesteryl esters (ChEs), specifically ChE(20:4) and ChE(18:2).

B. The CHPT1–LCAT Axis

• Pathway Identification: Lipidomic and siRNA screening revealed that DAG is converted to ChEs via a pathway involving CHPT1 (converting DAG to Phosphatidylcholine, PC) and LCAT (using PC as an acyl donor to esterify cholesterol).
• Genetic Validation: Knockout of CHPT1 or LCAT abolished DAGL-inhibition-induced ferroptosis and lipid peroxidation. Exogenous supplementation of ChEs rescued the ferroptosis resistance seen in ATGL-knockout cells, confirming ChEs act downstream of DAG routing.
• Intracellular LCAT (iLCAT):
  • LCAT exists in an intracellular pool (iLCAT) that lacks the signal peptide for secretion and is minimally glycosylated.
  • iLCAT is catalytically active in vitro without ApoA-I.
  • Spatial Coupling: iLCAT physically interacts with CHPT1 and co-localizes on Golgi and TGN membranes (marked by TGN46, GM130, Golgin-97), forming a spatially confined platform for ChE synthesis.

C. In Vivo Therapeutic Implications

• Cancer (Pro-Ferroptotic): In xenograft models, inhibiting DAG degradation (using DAGL inhibitors DO34/KT109) significantly suppressed tumor growth. This effect was synergistic with ferroptosis inducers (Sulfasalazine) and reversed by ferroptosis inhibitors (Liproxstatin-1), confirming the mechanism is ferroptosis-dependent.
• MASH (Anti-Ferroptotic): In a mouse model of MASH, hepatocyte-specific knockdown of CHPT1 or LCAT reduced hepatic ChE levels, lipid peroxidation (4-HNE, MDA), inflammation, and fibrosis. This treatment improved liver function (lower ALT/AST) and attenuated MASH pathology without significantly altering systemic lipid profiles, suggesting that blocking this specific intracellular routing protects the liver from ferroptotic damage.

5. Significance

This study redefines the understanding of ferroptosis regulation by shifting the focus from bulk lipid abundance to subcellular lipid routing. It reveals that the Golgi/TGN serves as a critical site for generating lethal lipid species via the CHPT1–LCAT axis.

• Biological Insight: It challenges the dogma that LCAT is exclusively a secreted plasma protein, revealing a functional intracellular pool that couples phospholipid remodeling to cell death.
• Therapeutic Strategy: The findings offer a "double-edged sword" therapeutic approach:
  1. Cancer: Enhancing DAG routing through the CHPT1–LCAT axis could induce ferroptosis to kill tumor cells.
  2. Metabolic Disease: Inhibiting this axis in hepatocytes could prevent ferroptosis-driven liver injury in MASH.
• Precision Medicine: The study suggests that targeting specific lipid-remodeling nodes (like CHPT1) rather than global lipid metabolism could provide therapeutic leverage with fewer systemic side effects.